AbbVie to Present Comprehensive Data on Antibody-Drug Conjugate Portfolio at ESMO 2025, Reinforcing Leadership in Targeted Solid Tumor Therapies
AbbVie (NYSE: ABBV) announced today that it will present a robust set of new clinical data from its antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, scheduled for October 17–21 in Berlin, Germany. The presentations will showcase results from investigational and approved ADCs across AbbVie’s oncology portfolio, including telisotuzumab adizutecan (Temab-A), ABBV-706, and Emrelis™ (telisotuzumab vedotin), focusing on patients with difficult-to-treat tumor types where significant unmet medical needs remain.
“Despite advances in the treatment of advanced solid tumors, many patients continue to face limited therapeutic options,” said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology, AbbVie. “The new data we are sharing at ESMO highlights our ongoing commitment to developing targeted therapies across a range of solid tumors and underscores the potential of our ADC platform to address critical patient needs.”
Key Highlights of AbbVie’s ESMO 2025 Presentations
AbbVie will feature three oral presentations focusing on Temab-A, a next-generation investigational ADC directed against c-Met with a novel topoisomerase 1 inhibitor (Top1i) payload. The data include Phase 1 results evaluating Temab-A both as monotherapy and in combination across various advanced solid tumors:
- Temab-A Combined with Bevacizumab in Advanced Colorectal Cancer (CRC): In biomarker-unselected patients with advanced CRC who had previously received three or more lines of therapy (NCT05029882), Temab-A administered at a 2.4 mg/kg dose in combination with bevacizumab (n=30) demonstrated an objective response rate (ORR) of 26.7%, compared to 0% in the standard-of-care arm treated with trifluridine/tipiracil plus bevacizumab (n=20). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 67% of patients receiving Temab-A combination therapy versus 65% in the comparator group.
- Temab-A Monotherapy in MET-Amplified Solid Tumors: In a cohort of 100 patients with advanced MET-amplified tumors—including non-small cell lung cancer (NSCLC, n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA, n=14), and 16 other tumor types (n=35)—Temab-A monotherapy achieved an ORR of 46% across all doses and tumor types. Higher responses were observed in NSCLC (69%) and GEA (71%). The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).
- Temab-A Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC): Among 42 biomarker-unselected patients with advanced or metastatic PDAC who had progressed on or after first-line therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients previously treated with gemcitabine-nab-paclitaxel. Grade ≥3 TEAEs occurring in ≥10% of patients included anemia (38%) and neutropenia (21%).
“Temab-A continues to demonstrate meaningful clinical activity across an expanding spectrum of solid tumors and patient populations, including those with MET amplification and elevated c-Met expression,” said Vivek Subbiah, M.D., Chief of Early-Phase Drug Development at Sarah Cannon Research Institute and Temab-A investigator. “These findings support the further clinical investigation of Temab-A across multiple solid tumor indications.”
ABBV-706 Phase 1 Data in Small Cell Lung Cancer (SCLC)
AbbVie will also present updated analyses from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory (R/R) SCLC (NCT05599984). A post hoc analysis compared progression-free survival (PFS) of patients receiving ABBV-706 monotherapy after progression on platinum-based standard-of-care (SOC) treatment with their initial PFS on 1L SOC. These findings suggest that ABBV-706 has the potential to serve as a first-line therapy alternative for patients with SCLC.
Additional data from the same study highlighted the rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) following ABBV-706 treatment. Patients achieving complete ctDNA clearance experienced significantly higher PFS and overall survival compared to those without ctDNA clearance, highlighting ctDNA as a potential early response biomarker. A Phase 2 study evaluating ABBV-706 in combination with atezolizumab as a potential replacement for platinum-based chemotherapy in first-line SCLC is ongoing (NCT07155174).
ESMO 2025 Presentation Schedule
AbbVie will deliver multiple presentations during ESMO 2025, spanning oral sessions, mini oral sessions, and poster presentations covering both investigational and approved ADCs. Key presentations include:
- Temab-A in MET-amplified solid tumors (oral presentation, Oct 19, Bremen Auditorium)
- Temab-A plus bevacizumab in advanced CRC (mini oral session, Oct 19, Cologne Auditorium)
- Temab-A in PDAC (mini oral session, Oct 20, Bonn Auditorium)
- ABBV-706 in R/R SCLC, including ctDNA and molecular response analyses (poster session, Oct 18)
- Mirvetuximab soravtansine (Elahere™) in platinum-resistant ovarian cancer (poster session, Oct 18)
Other posters and e-posters will present real-world data on c-Met overexpression in NSCLC, treatment outcomes following Teliso-V (telisotuzumab vedotin) dose modifications, ocular safety findings, and companion diagnostic development to identify patients likely to benefit from c-Met-targeted therapies.
